EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin

Masaki Shimizu, Wataru Ohwada, Toshiyuki Yano, Hidemichi Kouzu, Tatsuya Sato, Toshifumi Ogawa, Arata Osanami, Yuki Toda, Hiroshi Nagahama, Masaya Tanno, Tetsuji Miura, Atsushi Kuno und 1 weitere

Journal of Pharmacological Sciences · 2024

DOI: 10.1016/j.jphs.2024.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2024. Verfasst von Masaki Shimizu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Doxorubicin, Protein Kinases, Sirolimus, Cardiomyopathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Necroptosis, necrosis characterized by RIPK3-MLKL activation, has been proposed as a mechanism of doxorubicin (DOX)-induced cardiomyopathy. We showed that rapamycin, an mTORC1 inhibitor, attenuates cardiomyocyte necroptosis. Here we examined role of MLKL in DOX-induced myocardial damage and protective effects of rapamycin. Cardiomyopathy was induced in mice by intraperitoneal injections of DOX (10 mg/kg, every other day) and followed for 7 days. DOX-treated mice showed a significant decline in LVEF assessed by cardiac MRI (45.5 ± 5.1% vs. 65.4 ± 4.2%), reduction in overall survival rates, and increases in myocardial RIPK3 and MLKL expression compared with those in vehicle-treated mice, and those changes were prevented by administration of rapamycin (0.25 mg/kg) before DOX injection. In immunohistochemical analyses, p-MLKL signals were detected in the cardiomyocytes of DOX-treated mice, and the signals were reduced by rapamycin. Mlkl+/- and Mlkl-/- mice were similarly resistant to DOX-induced cardiac dysfunction, indicating that a modest reduction in MLKL level is sufficient to prevent the development of DOX-induced cardiomyopathy. However, evidence of cardiomyocyte necrosis assessed by C9 immunostaining, presence of replacement fibrosis, and electron microscopic analyses was negligible in the myocardium of DOX-treated mice. Thus, MLKL-mediated signaling contributes to DOX-induced cardiac dysfunction primarily by a necrosis-independent mechanism, which is inhibitable by rapamycin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinProtein KinasesSirolimusCardiomyopathiesReceptor-Interacting Protein Serine-Threonine KinasesMyocytes, CardiacMice, Inbred C57BLNecroptosisAnimalsMaleMiceAntibiotics, Antineoplastic

Stichwörter der Autor:innen

CardiomyopathyDoxorubicinMLKLNecroptosisRapamycin

Substanzen

DoxorubicinProtein KinasesSirolimusMLKL protein, mouseReceptor-Interacting Protein Serine-Threonine KinasesRipk3 protein, mouseAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. Electronic address: tyano@sapmed.ac.jp.
  • Department of Cellular Physiology and Signal Transduction, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Division of Radioisotope Research, Biomedical Research, Education and Instrumentation Center, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Nursing, Division of Medical and Behavioral Subjects, Sapporo Medical University School of Health Sciences, Sapporo, Japan.
  • Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan.

Zitieren

APA

Shimizu, M., Ohwada, W., Yano, T., Kouzu, H., Sato, T., Ogawa, T., Osanami, A., Toda, Y., Nagahama, H., Tanno, M., Miura, T., Kuno, A., & Furuhashi, M. (2024). Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin. Journal of Pharmacological Sciences. https://doi.org/10.1016/j.jphs.2024.06.005

Vancouver

Shimizu M, Ohwada W, Yano T, Kouzu H, Sato T, Ogawa T, et al. Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin. Journal of Pharmacological Sciences. 2024. doi:10.1016/j.jphs.2024.06.005

BibTeX
@article{Shimizu2024,
  author = {Shimizu, Masaki and Ohwada, Wataru and Yano, Toshiyuki and Kouzu, Hidemichi and Sato, Tatsuya and Ogawa, Toshifumi and Osanami, Arata and Toda, Yuki and Nagahama, Hiroshi and Tanno, Masaya and Miura, Tetsuji and Kuno, Atsushi and Furuhashi, Masato},
  title = {Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin},
  journal = {Journal of Pharmacological Sciences},
  year = {2024},
  doi = {10.1016/j.jphs.2024.06.005}
}
Kostenlos starten →